Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Proteomics International Laboratories Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50M | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | 1.46M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -6.74M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -7.11M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 7.02M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 5.33M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 247.67K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 1.74M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 5.46M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -5.51M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -5.46M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -46.19K | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 5.87M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Proteomics International Laboratories Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$90.43M | -9.45 | -49.72% | ― | ― | 10.78% | |
54 Neutral | AU$53.20M | -5.38 | -71.87% | ― | 7.65% | -19.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$166.28M | ― | ― | ― | ― | 0.66% | |
42 Neutral | AU$10.93M | -1.69 | -469.35% | ― | ― | 46.28% | |
34 Underperform | AU$66.74M | -1.35 | -100.67% | ― | 1114.27% | 85.66% |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Laboratories Ltd responded to an ASX price query, clarifying that recent trading activity in its securities is likely due to several significant announcements. These include the US Medicare setting a reimbursement price for their PromarkerD test, which supports their US launch strategy, and new data on their OxiDx test indicating its potential to improve racehorse performance. The company has also achieved milestones such as clinical certification for its Australian diagnostics laboratory and initial sales of PromarkerD and PromarkerEso in Australia. These developments have likely contributed to increased investor interest.
Proteomics International Laboratories Ltd announced that the US Centers for Medicare & Medicaid Services (CMS) has set a reimbursement price for their PromarkerD test, a predictive diagnostic for diabetic kidney disease, at $390.75. This decision is a significant milestone for the company, enhancing their US launch strategy by facilitating broader patient access and strengthening discussions with private payers. The PromarkerD test, which can predict diabetic kidney disease up to four years before symptoms appear, has the potential to improve care for over 32 million adults in the US with diabetes, reduce healthcare costs, and drive adoption and commercial partnerships.
Proteomics International Laboratories Ltd has announced the quotation of 50,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code PIQ. This move is part of the company’s ongoing efforts to enhance its market presence and provide additional value to its stakeholders by leveraging its expertise in proteomics.
Proteomics International Laboratories Ltd announced the issuance of new unquoted equity securities, specifically options expiring in 2028 and 2029. This move may impact the company’s financial strategy and provide additional resources for its ongoing projects, potentially strengthening its position in the biotechnology sector.
Proteomics International Laboratories Ltd announced a change in the director’s interest, specifically regarding Neville Gardiner’s indirect holdings. The announcement detailed the expiration of 250,000 unquoted options that were not exercised, impacting the director’s indirect interest holdings. This change reflects the company’s ongoing management of its securities and may influence stakeholder perceptions of the company’s governance practices.
Proteomics International Laboratories Ltd announced the cessation of 375,000 securities under the ASX code PIQAZ, which expired on November 24, 2025, without being exercised or converted. This announcement may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.
Proteomics International Laboratories Ltd announced that all resolutions at their Annual General Meeting were passed by poll. This outcome reflects strong shareholder support and may positively influence the company’s strategic initiatives and governance, potentially enhancing its position in the medical technology sector.
Proteomics International Laboratories Ltd announced at its Annual General Meeting that Richard, the founding Managing Director, will retire in early 2026 after 25 years with the company. The recruitment process for his successor is well underway, ensuring a smooth leadership transition. The company acknowledged Richard’s significant contributions and the promising future opportunities for Proteomics International.
Proteomics International Laboratories Ltd announced its participation in the Bell Potter Healthcare Conference 2025, where Dr. Richard Lipscombe will present on the company’s advancements. This engagement underscores the company’s commitment to showcasing its innovative diagnostic solutions, potentially enhancing its industry position and stakeholder engagement.
Proteomics International Laboratories Ltd has bolstered its cash reserves with a $2.2 million R&D tax incentive for the 2024-25 financial year. This funding supports the commercialization of their diagnostic tests, including Promarker®D for Diabetic Kidney Disease and Promarker®Endo for Endometriosis, as well as their ongoing R&D efforts. The rebate, part of the Australian Government’s initiative to encourage beneficial research, highlights the company’s commitment to advancing its diagnostic pipeline and strengthening its market position.
Proteomics International Laboratories Ltd has received a $500,000 grant from the Western Australian Government to support the commercialization of PromarkerEndo, a pioneering blood test for diagnosing endometriosis. This funding will aid in regulatory, marketing, and partnership efforts, addressing the global health challenge of endometriosis, which affects one in nine women. The test offers a non-invasive alternative to current diagnostic methods, potentially transforming women’s healthcare by reducing the average seven-year diagnosis time, and is expected to launch in Australia in the second half of 2025.
Proteomics International Laboratories Ltd has achieved significant milestones, including receiving ISO 15189 certification for its Australian laboratory operations, which supports the commercialization of its precision diagnostic tests like PromarkerD and PromarkerEso. The company is expanding its market presence with the national launch of PromarkerD for diabetic kidney disease prediction and PromarkerEso for esophageal cancer diagnosis in Australia, alongside preparations for the PromarkerEndo test for endometriosis. These developments, coupled with a strategic go-to-market approach embracing telehealth trends, position the company for potential partnerships and revenue growth in the precision diagnostics sector.
Proteomics International Laboratories Ltd has announced its upcoming Annual General Meeting, scheduled for 21 November 2025. The company has opted for digital distribution of the Notice of Meeting, encouraging shareholders to access documents online and submit proxy votes electronically, reflecting a modern approach to shareholder engagement.
Proteomics International Laboratories Ltd has announced the appointment of Vicki Robinson as a new director, effective from October 14, 2025. The initial director’s interest notice indicates that Robinson currently holds no securities in the company, which suggests a neutral impact on the company’s stock ownership structure. This appointment could potentially influence the company’s strategic direction, given Robinson’s role on the board.
Proteomics International Laboratories Ltd has expanded its collaboration with the University of Melbourne and the Royal Women’s Hospital to enhance the PromarkerEndo blood test for diagnosing endometriosis. This partnership aims to provide additional clinical validation and develop a next-generation tissue-specific test, addressing a significant global health need. The collaboration seeks to reduce the average seven-year diagnostic delay for endometriosis, potentially transforming women’s healthcare by offering a non-invasive diagnostic option. The agreement includes commercial terms granting Proteomics International an exclusive license to commercialize new intellectual property developed under the project.
Proteomics International Laboratories Ltd announced the appointment of Ms. Vicki Robinson as an independent non-executive director. With over 20 years of experience in executive and governance roles, Ms. Robinson is expected to enhance the company’s strategic and decision-making capabilities. Her appointment comes at a crucial time as Proteomics International rolls out its leading diagnostic products, which have the potential to transform the management of chronic conditions such as diabetic kidney disease, endometriosis, and esophageal cancer.
Proteomics International Laboratories Ltd announced the issuance of 375,000 unquoted equity securities, specifically options expiring on June 6, 2027, with an exercise price of $0.555. This issuance is part of a previously announced transaction, and these securities are not intended to be quoted on the ASX. The move reflects the company’s ongoing efforts to manage its equity and financial strategy, potentially impacting its market positioning and stakeholder interests.
Proteomics International Laboratories Ltd announced the issuance of 409,600 unquoted employee performance rights as part of an incentive scheme. These securities are restricted from transfer and will not be quoted on the ASX until the restriction period ends, indicating a strategic move to motivate and retain talent within the company.
Proteomics International Laboratories Ltd has announced the presentation of its PromarkerEso diagnostic test results at the World Congress for Esophageal Diseases. The test, which detects early stages of esophageal adenocarcinoma with high accuracy, is now available across Australia through telehealth consultations and physician referrals. This development could significantly improve health outcomes by enabling earlier diagnosis and treatment of esophageal cancer, a condition often diagnosed too late for effective intervention.
Proteomics International Laboratories Ltd has achieved ISO 15189 certification for its Australian laboratory operations, marking a significant milestone in the commercialization and clinical application of its precision diagnostic tests. This certification enhances the company’s reputation as a global leader in proteomics and protein-based testing services, supporting its strategic growth and enabling the offering of new specialist pathology tests. The certification is expected to open new revenue streams and solidify the company’s position as an innovator in precision diagnostics, particularly in areas like diabetic kidney disease, esophageal cancer, and endometriosis.
Proteomics International Laboratories Ltd has announced its Annual General Meeting (AGM) will be held on November 21, 2025, at the Harry Perkins Institute. The deadline for director nominations is October 3, 2025. Details of the AGM agenda and resolutions will be shared in the Notice of Meeting, with a video recording available to shareholders post-event. This announcement is part of the company’s ongoing commitment to transparency and shareholder engagement.
Proteomics International Laboratories Ltd announced a planned transition in its Board and Management, with Managing Director Dr. Richard Lipscombe set to retire in February 2026, marking his 25th anniversary with the company. The transition aims to strengthen the company’s leadership as it continues to commercialize its world-class technology in precision diagnostics and precision medicine. A specialist biotechnology executive search firm has been appointed to find a new CEO with global experience in diagnostics, medical technology, and digital health commercialisation. Dr. Lipscombe will remain in his role until a successor is appointed, ensuring a smooth transition.
Proteomics International Laboratories Ltd announced that their PromarkerEso blood test has shown high accuracy in diagnosing early stages of esophageal adenocarcinoma (EAC), a common form of esophageal cancer often caused by chronic acid reflux. This advancement could significantly improve early detection rates, offering a less invasive alternative to current diagnostic methods and potentially enhancing survival rates for patients, as EAC is often diagnosed too late for effective treatment.